Anselamimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A chimeric monoclonal antibody specifically targeting human immunoglobulin light chain (LC)-related fibrils, which may potentially be used in the treatment of light chain-associated (AL) amyloidosis. Upon administration, anselamimab targets and binds to the amyloid-related, conformational epitope on LC-related fibrils. This inhibits fibrillogenesis, induces an Fc-mediated cellular inflammatory response, increases degradation and elimination of AL amyloidomas, and prevents systemic LC-associated amyloid deposits. In AL amyloidosis the amyloid fibrils are composed of immunoglobulin light chain fragments.

**Synonyms:** - 11-1F4 - 111F4 - ANSELAMIMAB - CAEL 101 - CAEL-101 - CAEL101 - Chimeric Amyloid-reactive Monoclonal Antibody CAEL-101 - Chimeric Fibril-reactive Monoclonal Antibody CAEL-101 - Chimeric Fibril-reactive Monoclonal Antibody CAEL-101 - c11-1F4 mAb - mAb-11-1F4